ArticleCureus2026
Audit of Retinal Screening Protocol Adherence Among Patients Receiving Hydroxychloroquine at the Department of Rheumatology, Gulab Devi Teaching Hospital, Pakistan.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHydroxychloroquine (HCQ) is a widely used drug for various rheumatological conditions. Long-term use may be associated with retinal toxicity, which is often asymptomatic in the early stages and may lead to irreversible vision loss. Regular retinal screening is recommended in patients on long-term HCQ therapy. This audit assessed compliance with HCQ retinal screening protocols and evaluated changes in adherence following targeted interventions. MATERIALS AND
methodsA two-cycle clinical audit was conducted in the Department of Rheumatology, Gulab Devi Teaching Hospital, Lahore, Pakistan. The first cycle (August-October 2025) included 50 patients receiving HCQ therapy. Data were collected using a structured proforma through review of medical records and patient interviews. Three indicators, based on the 2016 American Academy of Ophthalmology (AAO) recommendations, were assessed: baseline retinal screening within one year of HCQ initiation, annual screening in patients on HCQ for ≥5 years, and early screening in high-risk patients (<5 years of therapy). High-risk patients were defined as those with one or more recognized risk factors for HCQ retinopathy, including an HCQ dose >5 mg/kg/day based on actual body weight, renal impairment, pre-existing macular disease, or concurrent tamoxifen use, and receiving HCQ for less than five years. Documentation of ophthalmology referral was also assessed. Interventions included patient counselling, educational leaflets, mandatory ophthalmology referral, structured documentation of high-risk status, and improved coordination with ophthalmology services. The second cycle (February-April 2026) included 50 new, non-overlapping patients assessed using the same methodology.
resultsIn Phase 1, baseline retinal screening was documented in 12.0% (6/50), while 88.0% (44/50) had no record of screening. Annual screening in long-term users was 15.4% (4/26), and high-risk early screening was 9.1% (1/11). Ophthalmology referral was documented in 18.0% (9/50). Following interventions, baseline screening improved to 100% (50/50; p < 0.001). Annual screening improved to 76.0% (19/25; p < 0.001), and high-risk screening improved to 75.0% (9/12; p = 0.003). Ophthalmology referral improved to 100% (50/50; p < 0.001).
conclusionBaseline adherence to HCQ retinal screening was poor initially. Following structured interventions including counselling, referral pathways, and improved documentation, significant improvement was observed across all indicators. Some gaps remain in follow-up screening, particularly annual and high-risk monitoring, highlighting the need for continued reinforcement of guideline-based practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.